Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. (Q47161862)

10 January 2018

title

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. (English)

1 reference

10 January 2018

1 reference

18

Michael Lim

1 reference

10 January 2018

Chetan Bettegowda

15

Chetan Bettegowda

1 reference

10 January 2018

Tomas Garzon-Muvdi

7

Tomas Garzon-Muvdi

1 reference

10 January 2018

Henry Brem

16

Henry Brem

1 reference

10 January 2018

Christopher Jackson

6

Christopher M Jackson

1 reference

10 January 2018

author name string

Dimitrios Mathios

1

1 reference

10 January 2018

Jennifer E Kim

2

1 reference

10 January 2018

Antonella Mangraviti

3

1 reference

10 January 2018

Jillian Phallen

4

1 reference

10 January 2018

Chul-Kee Park

5

1 reference

10 January 2018

Eileen Kim

8

1 reference

10 January 2018

Debebe Theodros

9

1 reference

10 January 2018

Magdalena Polanczyk

10

1 reference

10 January 2018

Allison M Martin

11

1 reference

10 January 2018

Ian Suk

12

1 reference

10 January 2018

Xiaobu Ye

13

1 reference

10 January 2018

Betty Tyler

14

1 reference

10 January 2018

Drew M Pardoll

17

1 reference

10 January 2018

language of work or name

English

0 references

publication date

1 December 2016

1 reference

10 January 2018

Science Translational Medicine

published in

1 reference

10 January 2018

volume

8

1 reference

10 January 2018

issue

370

1 reference

10 January 2018

page(s)

370ra180

1 reference

10 January 2018

Nivolumab: targeting PD-1 to bolster antitumor immunity

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Profound impairment of adaptive immune responses by alkylating chemotherapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Vaccine strategies for glioblastoma: progress and future directions

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

The blockade of immune checkpoints in cancer immunotherapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Combining immunotherapy with chemotherapy to treat cancer.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Pharmacokinetics of the carmustine implant

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5724383

10.1126/SCITRANSLMED.AAG2942

15 August 2018

Identifiers

DOI

1 reference

10 January 2018

PMC publication ID

5724383

1 reference

10 January 2018

PubMed publication ID

28003545

1 reference

10 January 2018